Boston Advisors LLC lifted its stake in shares of Amedisys Inc (NASDAQ:AMED) by 1.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 47,529 shares of the health services provider’s stock after buying an additional 852 shares during the period. Boston Advisors LLC owned approximately 0.15% of Amedisys worth $6,227,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of AMED. FMR LLC grew its stake in shares of Amedisys by 13.4% in the 1st quarter. FMR LLC now owns 370,789 shares of the health services provider’s stock valued at $45,703,000 after buying an additional 43,844 shares during the period. WINTON GROUP Ltd lifted its holdings in shares of Amedisys by 91.8% in the 2nd quarter. WINTON GROUP Ltd now owns 5,520 shares of the health services provider’s stock worth $670,000 after acquiring an additional 2,642 shares during the last quarter. Retirement Systems of Alabama lifted its holdings in shares of Amedisys by 122.7% in the 2nd quarter. Retirement Systems of Alabama now owns 84,431 shares of the health services provider’s stock worth $10,251,000 after acquiring an additional 46,512 shares during the last quarter. Riverbridge Partners LLC acquired a new position in shares of Amedisys in the 2nd quarter worth approximately $80,465,000. Finally, First Citizens Bank & Trust Co. acquired a new position in shares of Amedisys in the 2nd quarter worth approximately $392,000. Institutional investors and hedge funds own 90.90% of the company’s stock.
Shares of AMED stock traded up $2.14 during mid-day trading on Wednesday, hitting $166.71. The stock had a trading volume of 252,197 shares, compared to its average volume of 365,476. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.95 and a quick ratio of 0.95. Amedisys Inc has a fifty-two week low of $103.76 and a fifty-two week high of $167.37. The company’s 50-day simple moving average is $147.25 and its 200-day simple moving average is $130.93. The firm has a market cap of $5.38 billion, a PE ratio of 45.93, a PEG ratio of 2.26 and a beta of 1.47.
Amedisys (NASDAQ:AMED) last announced its earnings results on Tuesday, October 29th. The health services provider reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.25. The company had revenue of $494.63 million during the quarter, compared to analysts’ expectations of $494.14 million. Amedisys had a net margin of 6.70% and a return on equity of 26.53%. The firm’s quarterly revenue was up 18.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.95 earnings per share. On average, analysts expect that Amedisys Inc will post 4.39 EPS for the current year.
In other Amedisys news, COO Christopher Gerard sold 350 shares of Amedisys stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $134.79, for a total transaction of $47,176.50. Following the transaction, the chief operating officer now directly owns 25,381 shares of the company’s stock, valued at $3,421,104.99. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Donald A. Washburn sold 8,667 shares of the business’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $149.96, for a total transaction of $1,299,703.32. Following the transaction, the director now directly owns 36,698 shares in the company, valued at $5,503,232.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,407 shares of company stock valued at $2,694,756. Insiders own 2.90% of the company’s stock.
Several brokerages have recently commented on AMED. ValuEngine lowered shares of Amedisys from a “buy” rating to a “hold” rating in a report on Thursday, September 26th. Stephens reiterated an “equal weight” rating and set a $145.00 target price on shares of Amedisys in a report on Tuesday, October 22nd. Robert W. Baird upgraded shares of Amedisys from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $140.00 to $160.00 in a report on Friday, November 1st. Deutsche Bank started coverage on shares of Amedisys in a report on Monday, September 16th. They set a “buy” rating and a $155.00 target price on the stock. Finally, Bank of America increased their target price on shares of Amedisys from $170.00 to $178.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Five investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $147.20.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
See Also: What is meant by a buy rating?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.